ABSTRACT
Introduction Design thinking (DT), a methodology for solving complex problems, has the potential to create powerful, human-centred healthcare improvement. We applied DT methodology to the context of peripheral arterial disease (PAD). PAD is increasingly prevalent globally and associated with significant morbidity and mortality. We fall short of achieving effective secondary prevention due to persistent underdiagnosis and undertreatment of this disease. In this study, we sought to identify novel and creative solutions to improve diagnosis and secondary prevention of PAD.
Methods We describe the initial ‘Empathize’, ‘Define’, and ‘Ideate’ stages of the five-stage DT model proposed by the Hasso Plattner Institute of Design at Stanford University. We engaged patients with PAD, caregivers, clinicians, and other stakeholders in a co-design process using semi-structured interviews, a DT workshop, and post-workshop survey. Data from the interviews and workshop were analyzed using inductive thematic analysis, and data from the survey were analyzed using an idea prioritization matrix.
Results Exploring the lived experience of those with PAD and those delivering PAD care emphasized the influence of system-level barriers. Many of the solutions proposed by workshop participants target evidence-based, system-level interventions through improved funding support, institutional support, outreach efforts and technological applications. The connections between insights derived in the ‘Empathize’ stage and solutions proposed during the ‘Ideate’ stage showed the success of the co-design process in inspiring empathy-driven solutions.
Discussion This study demonstrates how DT methodology can be applied to complex healthcare problems such as PAD care, to systematically develop human-centred solutions. In the next stages of this study, we will use the results of this co-design process to iteratively implement, evaluate, and optimize the proposed solutions which were prioritized as being most feasible and high impact.
What is already known on this topic Peripheral arterial disease (PAD) is increasingly prevalent globally. The significant morbidity and mortality associated with PAD can be reduced with timely diagnosis and the effective use of secondary preventative therapies; however, PAD remains underdiagnosed and undertreated compared to other atherosclerotic diseases.
What this study adds This study is novel in its application of design thinking methodology and a co-design approach to work together with people with lived experience of PAD, to establish priorities for PAD care.
How this study may affect research, practice or policy – Insights from this study emphasize system-level barriers which prevent effective delivery and uptake of PAD care. Solutions that are human-centred and co-produced with patients and key stakeholders should improve institutional and governmental support for implementation of evidence-based best practices; this will be investigated further in the next stages of this study.
Competing Interest Statement
Dr. Bhagirath has received honoraria from Bayer and an unrestricted educational grant from Pfizer. Dr. Anand Dr. Anand has received speaking honoraria and consultancy fees from Bayer, Janssen Pharmaceuticals, Novartis Pharmaceuticals Canada, Novo Nordisk, and Daiichi Sankyo.
Funding Statement
This study was funded by an unrestricted grant from Bayer. Dr. Anand holds the Heart and Stroke Michael G. DeGroote Chair in Population Health Research, and the Canada Research Chair Tier 1 in Ethnic Diversity and Cardiovascular Disease (#CRC-2017-00024).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Hamilton Integrated Research Ethics Board waived ethical approval for this work after a review of the intended process.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
